Review
doi: 10.1007/978-3-0348-7262-1_18.
The use of gamma-linolenic acid in diabetic neuropathy
Affiliations
- PMID: 1321553
- DOI: 10.1007/978-3-0348-7262-1_18
Item in Clipboard
Review
The use of gamma-linolenic acid in diabetic neuropathy
Agents Actions Suppl.
1992.
Abstract
EF4 is an entirely new approach to the management of diabetic neuropathy. EF4 (providing gamma-linolenic acid or gamolenic acid, GLA) has been shown to reverse existing diabetic neuropathy in trials in seven centres. Diabetic animals and humans have a reduced ability to convert dietary linoleic acid to GLA. GLA and its metabolites are required for normal neuronal structure and function and a normal microcirculation. The lack of GLA and its metabolites may play a major role in the development of the neuropathy. EF4 helps to correct the biochemical defects, restores levels of GLA metabolites towards normal and produces highly significant clinical and neurophysiological improvements in diabetic neuropathy.
Similar articles
-
Treatment of diabetic neuropathy with gamma-linolenic acid. The gamma-Linolenic Acid Multicenter Trial Group.Diabetes Care. 1993 Jan;16(1):8-15. doi: 10.2337/diacare.16.1.8. Diabetes Care. 1993. PMID: 8380765 Clinical Trial.
-
The effect of gamma-linolenic acid on human diabetic peripheral neuropathy: a double-blind placebo-controlled trial.Diabet Med. 1990 May;7(4):319-23. doi: 10.1111/j.1464-5491.1990.tb01397.x. Diabet Med. 1990. PMID: 2159860 Clinical Trial.
-
The effects of gamma-linolenic acid on breast pain and diabetic neuropathy: possible non-eicosanoid mechanisms.Prostaglandins Leukot Essent Fatty Acids. 1993 Jan;48(1):101-4. doi: 10.1016/0952-3278(93)90016-p. Prostaglandins Leukot Essent Fatty Acids. 1993. PMID: 8380930 Review.
-
Gamma-linolenic acid in diabetic neuropathy.Lancet. 1986 May 10;1(8489):1098. doi: 10.1016/s0140-6736(86)91365-6. Lancet. 1986. PMID: 2871365 Clinical Trial. No abstract available.
-
Essential fatty acids in the management of impaired nerve function in diabetes.Diabetes. 1997 Sep;46 Suppl 2:S90-3. doi: 10.2337/diab.46.2.s90. Diabetes. 1997. PMID: 9285506 Review.
Cited by
-
Biomanufacturing of γ-linolenic acid-enriched galactosyldiacylglycerols: Challenges in microalgae and potential in oleaginous yeasts.Synth Syst Biotechnol. 2023 Jul 7;8(3):469-478. doi: 10.1016/j.synbio.2023.06.007. eCollection 2023 Sep. Synth Syst Biotechnol. 2023. PMID: 37692201 Free PMC article. Review.
-
Is Nerve Electrophysiology a Robust Primary Endpoint in Clinical Trials of Treatments for Diabetic Peripheral Neuropathy?Diagnostics (Basel). 2022 Mar 17;12(3):731. doi: 10.3390/diagnostics12030731. Diagnostics (Basel). 2022. PMID: 35328284 Free PMC article. Review.
-
Recent advances and future directions on GLA-producing organisms.Front Bioeng Biotechnol. 2025 Jul 9;13:1567840. doi: 10.3389/fbioe.2025.1567840. eCollection 2025. Front Bioeng Biotechnol. 2025. PMID: 40704100 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Other Literature Sources
Medical